Suppr超能文献

血管性水肿通过抗组胺药和白三烯调节剂的联合使用得到抑制。

Angioedema suppressed by a combination of anti-histamine and leukotriene modifier.

作者信息

Wong Brendan N, Vadas Peter

机构信息

Division of Allergy and Clinical Immunology, Department of Medicine, St. Michael's Hospital, Toronto, Canada.

出版信息

Allergy Asthma Clin Immunol. 2017 Jun 13;13:28. doi: 10.1186/s13223-017-0201-1. eCollection 2017.

Abstract

RATIONALE

Angioedema without co-existent urticaria is due to a limited number of causes, including hereditary and acquired C1 esterase inhibitor deficiency, drug-induced angioedema or idiopathic histaminergic or non-histaminergic angioedema. We describe a cohort of patients with recurrent angioedema whose clinical features and response to medications are distinct from the causes above.

METHODS

Patients were accrued retrospectively from an academic allergy practice between 2007 and 2014. After institutional research ethics board approval, patients' charts were reviewed and demographic, clinical and laboratory data were extracted.

RESULTS

A total of 11 patients were recruited. The mean age at presentation was 54.9 years (range 19-70 years) and 6 of 11 were male. The mean number of episodes per year was 18.7 (range 2-60) and mean duration of episodes was 22.4 h (range 4-96). About half of episodes (52%) began overnight. Areas of involvement were lips (73%), tongue (64%), eyelids (18%), feet (36%) and hands (27%). None of the patients had low C3, C4, or CH50; none had significantly positive ANA; C1 esterase inhibitor level and function and C1q were normal in all patients tested. In these 11 patients, complete suppression of recurrences by the combination of cetirizine 20 mg daily and montelukast 10 mg daily was reported by 9 (82%) of patients; whereas 2 (18%) of patients had a partial response to this combination of medications.

CONCLUSIONS

Herein, we report a form of angioedema without urticaria, mediated by a combination of histamine and leukotrienes. Clinical, demographic and therapeutic characteristics differentiate this from other recognized causes of angioedema.

摘要

理论依据

无伴发荨麻疹的血管性水肿病因有限,包括遗传性和获得性C1酯酶抑制剂缺乏、药物性血管性水肿或特发性组胺能或非组胺能血管性水肿。我们描述了一组复发性血管性水肿患者,其临床特征和对药物的反应与上述病因不同。

方法

对2007年至2014年间一家学术性过敏诊所的患者进行回顾性招募。经机构研究伦理委员会批准后,查阅患者病历并提取人口统计学、临床和实验室数据。

结果

共招募了11名患者。就诊时的平均年龄为54.9岁(范围19 - 70岁),11名患者中有6名男性。每年发作的平均次数为18.7次(范围2 - 60次),发作的平均持续时间为22.4小时(范围4 - 96小时)。约一半的发作(52%)在夜间开始。受累部位包括嘴唇(73%)、舌头(64%)、眼睑(18%)、足部(36%)和手部(27%)。所有患者的C3、C4或CH50均不低;ANA均无明显阳性;所有检测患者的C1酯酶抑制剂水平和功能以及C1q均正常。在这11名患者中,9名(82%)患者报告每日联合使用20mg西替利嗪和10mg孟鲁司特可完全抑制复发;而2名(18%)患者对这种联合用药有部分反应。

结论

在此,我们报告了一种由组胺和白三烯共同介导的无荨麻疹的血管性水肿形式。临床、人口统计学和治疗特征将其与其他已知的血管性水肿病因区分开来。

相似文献

2
Idiopatic angioedema treated with dapsone.用氨苯砜治疗的特发性血管性水肿。
Allergol Immunopathol (Madr). 2005 Jan-Feb;33(1):54-6. doi: 10.1157/13070610.
8
"Nuts and Bolts" of Laboratory Evaluation of Angioedema.血管性水肿实验室评估的“基本要点”
Clin Rev Allergy Immunol. 2016 Oct;51(2):140-51. doi: 10.1007/s12016-016-8539-6.
9
[Angioedema].[血管性水肿]
Rev Alerg Mex. 2016 Oct-Dec;63(4):373-384. doi: 10.29262/ram.v63i4.220.
10
Novelties in the Diagnosis and Treatment of Angioedema.血管性水肿的诊断和治疗新进展。
J Investig Allergol Clin Immunol. 2016;26(4):212-21; quiz two pages after page 221. doi: 10.18176/jiaci.0087.

本文引用的文献

2
"Nuts and Bolts" of Laboratory Evaluation of Angioedema.血管性水肿实验室评估的“基本要点”
Clin Rev Allergy Immunol. 2016 Oct;51(2):140-51. doi: 10.1007/s12016-016-8539-6.
3
Angioedema Phenotypes: Disease Expression and Classification.血管性水肿的表型:疾病表现与分类
Clin Rev Allergy Immunol. 2016 Oct;51(2):162-9. doi: 10.1007/s12016-016-8541-z.
5
Current treatment options for idiopathic angioedema.特发性血管性水肿的当前治疗选择。
Ann Allergy Asthma Immunol. 2015 Nov;115(5):429-33. doi: 10.1016/j.anai.2015.07.023. Epub 2015 Sep 1.
9
Chronic idiopathic angioedema: a single center experience.慢性特发性血管性水肿:单中心经验
Int J Dermatol. 2014 Oct;53(10):e421-7. doi: 10.1111/ijd.12601. Epub 2014 Sep 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验